Skip to content
Screener

Bioventus BVS Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price at other companies

Palantir Technologies Inc. logo
Palantir Technologies Inc.PLTR
$8.89+15.0%
Zillow Group, Inc. logo
Zillow Group, Inc.ZG
$48.43+4.2%
BillionToOne, Inc. logo
BillionToOne, Inc.BLLN
$7.66—
Bank of Marin Bancorp logo
Bank of Marin BancorpBMRC
$35.22+5.3%
Maplebear Inc. logo
Maplebear Inc.CART
$12.05+3.1%
Groupon, Inc. logo
Groupon, Inc.GRPN
$0.00-100%

Other financials

Income statement

See full
Revenue$153.2M+3.8%
Gross profit$105.7M+3.5%
Operating income$19.1M+4.1%
Net income$33.4M+348%
EPS (diluted)$0.47+327%

Balance sheet

See full
Cash & equivalents$29.5M-10.5%
Total debt$263.7M-26.9%
Total equity$228.3M+41.6%
Total assets$673.3M-4.7%

Cash flow

See full
Operating cash flow$19.9M-23.4%
CapEx$960.0K+40.6%
Free cash flow$18.9M-25.1%

Valuation

See full
Market cap$1.19B+156%
Enterprise value$1.42B+79.7%
P/E21.8×—
P/S2×+1.2×

Profitability

See full
Gross margin68.7%+1.1pp
Operating margin10%—
Net margin9.4%+9.2pp
FCF margin16.2%+10.2pp

Returns & leverage

See full
Return on equity28%+27.5pp
Debt / equity1.2×-1.1×
Current ratio1.7×+0.2×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice.

The source filing: Bioventus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:43 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001665988-26-000042
Line itemNumber of optionsWeighted-average exercise priceWeighted-average remaining contractual termAggregate intrinsic value(1)
Outstanding at December 31, 20254,664$7.777.06$7,780
Granted1,0478.60
Exercised(55)4.03
Forfeited or canceled(67)9.26
Outstanding at June 27, 20265,589$7.947.12$14,750
Exercisable and vested at June 27, 20263,079$8.565.90$8,130

Item 1. Financial Statements (Unaudited)

FAQ

What is Bioventus's share based compensation arrangement by share based payment award options vested and expected to vest exercisable weighted average exercise price?
Bioventus (BVS) reported share based compensation arrangement by share based payment award options vested and expected to vest exercisable weighted average exercise price of $8.56 in Q2 2026.
How has Bioventus's share based compensation arrangement by share based payment award options vested and expected to vest exercisable weighted average exercise price changed year-over-year?
Bioventus's share based compensation arrangement by share based payment award options vested and expected to vest exercisable weighted average exercise price decreased by 5.9% year-over-year, from $9.10 to $8.56.
What does share based compensation arrangement by share based payment award options vested and expected to vest exercisable weighted average exercise price mean?
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price as reported by Bioventus Inc. Class A Common Stock.

Ask your AI about Bioventus's share based compensation arrangement by share based payment award options vested and expected to vest exercisable weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude